Microarray-based gene expression analysis holds promise of improving prognostication and treatment decisions for breast cancer patients. However, the heterogeneity of breast cancer emphasizes the need for validation of prognostic gene signatures in larger sample sets stratified into relevant subgroups. Here, we describe a multifunctional user-friendly online tool, GOBO (http://co.bmc.lu.se/gobo), allowing a range of different analyses to be performed in an 1881-sample breast tumor data set, and a 51-sample breast cancer cell line set, both generated on Affymetrix U133A microarrays. GOBO supports a wide range of applications including: 1) rapid assessment of gene expression levels in subgroups of breast tumors and cell lines, 2) identificati...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
We investigated the prognostic significance of Her2/neu expression using FDA approved Herceptest® an...
In the last decade, the development of microarrays and the ability to perform massively parallel gen...
Validating prognostic or predictive candidate genes in appropriately powered breast cancer cohorts a...
Validating prognostic or predictive candidate genes in appropriately powered breast cancer cohorts a...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Abstract Background Breast cancer is a heterogeneous disease, presenting with a wide range of histol...
The transcriptome of breast cancers have been extensively screened with microarrays and large sets o...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Abstract: The most integrated approach toward understanding the multiple molecular events and mechan...
Breast cancer is a complex and clinically heterogeneous disease. The increase in knowledge of breast...
Abstract Background There is an urgent need for new prognostic markers of breast cancer metastases t...
Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed...
Analysis by DNA microarrays has led to the identification of molecular subtypes of breast carcinomas...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
We investigated the prognostic significance of Her2/neu expression using FDA approved Herceptest® an...
In the last decade, the development of microarrays and the ability to perform massively parallel gen...
Validating prognostic or predictive candidate genes in appropriately powered breast cancer cohorts a...
Validating prognostic or predictive candidate genes in appropriately powered breast cancer cohorts a...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Abstract Background Breast cancer is a heterogeneous disease, presenting with a wide range of histol...
The transcriptome of breast cancers have been extensively screened with microarrays and large sets o...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for ca...
Abstract: The most integrated approach toward understanding the multiple molecular events and mechan...
Breast cancer is a complex and clinically heterogeneous disease. The increase in knowledge of breast...
Abstract Background There is an urgent need for new prognostic markers of breast cancer metastases t...
Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed...
Analysis by DNA microarrays has led to the identification of molecular subtypes of breast carcinomas...
The identification of novel candidate markers is a key challenge in the development of cancer therap...
We investigated the prognostic significance of Her2/neu expression using FDA approved Herceptest® an...
In the last decade, the development of microarrays and the ability to perform massively parallel gen...